PPTDF
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -6.66 | $4.8B | -$1.3B |
| 2025 Q4 | -4.13 | $5.7B | -$991M |
| 2025 Q3 | -8.60 | $4.4B | -$2.1B |
| 2025 Q2 | -0.06 | $4.3B | -$9M |
| 2025 Q1 | -0.05 | $4.2B | -$70M |
| 2024 Q4 | -0.13 | $32M | -$658M |
| 2023 Q2 | -3.70 | $4.5B | $814M |
| 2023 Q1 | -1.92 | $5.0B | $7.4B |